Categories: Business

Zeki Data Launches Company Diagnostics to Expose Hidden Risks in Deep-Tech Firms

LONDON, Sept. 11, 2025 /PRNewswire/ — Zeki Data, the UK-based deep-tech intelligence firm, today unveiled Company Diagnostics, a breakthrough tool that reveals organisational health and hidden risks inside deep-tech companies—far beyond what financials or pitch decks disclose.

- Advertisement -

Drawing on Zeki’s global Talent IQ dataset, Company Diagnostics combines workforce, financial, and competitive signals to deliver a clear, predictive view of execution strength and scaling capability. Organizations may select to receive concise, expert-authored reports or structured datasets for integration into investment and strategy workflows.

- Advertisement -

In deep-tech, the real indicator of future innovation is hidden in the people, not just the numbers,” said Tom Hurd, CEO & Co-Founder of Zeki Data. “Company Diagnostics surfaces overlooked signals—talent alignment, technical depth, and execution readiness—so investors and strategists can make decisions with confidence.”

- Advertisement -

Zeki is tracking 1,500 companies—700 listed and 800 private—across 30+ countries, covering 3 million professionals in 4,500 domains and 100+ deep-tech verticals. Reports leverage 50+ proprietary Zeki-Score metrics, updated monthly with a time series back to 2010.

- Advertisement -

Key benefits include:

- Advertisement -
  • Spot hidden risks — Detect attrition hotspots, weak scaling, and talent misalignments before they impact performance.
  • Link talent to outcomes — Map technical depth, innovation pedigree, and peer recognition to financial and market positioning.
  • Decision-ready delivery — Choose rapid PDF snapshots or full data feeds for deeper analysis and benchmarking.

Use cases:

- Advertisement -
  • Venture capital and private equity — enhance diligence, benchmark scaling momentum, and anticipate execution risks.
  • Public market investors — integrate innovation signals, identify anomalous hiring, and generate alpha opportunities.
  • M&A teams — validate technical depth and de-risk acquisitions before closing.

Delivery options include monthly data subscriptions or one-off PDF reports, supporting both continuous monitoring and single, high-stakes decisions. To request a demo or learn more, visit zekidata.com.

- Advertisement -

About Zeki Data

- Advertisement -

Zeki Data is a UK-based deep-tech intelligence company providing the most accurate human-capital and organisational diagnostics available. Its proprietary datasets track millions of scientists, engineers, and innovators worldwide. Founded by Tom Hurd, a former senior intelligence leader, Zeki applies counter-terrorism-grade analytics to business, helping clients forecast innovation potential and manage risk. Learn more at zekidata.com.

- Advertisement -

Logo – https://mma.prnewswire.com/media/2771135/Zeki_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/zeki-data-launches-company-diagnostics-to-expose-hidden-risks-in-deep-tech-firms-302553897.html

- Advertisement -
PRNW Agency

Recent Posts

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

ZUG, Switzerland, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Ms. Kazem brings extensive and global expertise…

5 days ago

Novartis Vanrafia Phase III data support slowing of kidney function decline in patients with IgA nephropathy

Basel, February 13, 2026 – Novartis today announced final results from the Phase III ALIGN…

2 weeks ago

January Commercial Chapter 11 Filings Increase 76% Over 2025

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- There were 956 commercial Chapter 11 filings…

2 weeks ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

Basel, February 6, 2026 – Novartis today broke ground on a new, state-of-the-art global Biomedical…

3 weeks ago

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjgrens disease

Basel, January 16, 2026 – Novartis today announced that the US Food and Drug Administration (FDA)…

1 month ago

Personar Appoints Former Genius Sports COO Eric Stevens as Chief Operating Officer to Scale Award-Winning Sports Technology Platform

Tuesday 13 January, 2026 LONDON – Tuesday, January 13, 2026 – Personar, the AI sports…

1 month ago